Protagonist Therapeutics Inc (NASDAQ:PTGX) Director Bryan Giraudo bought 10,000 shares of the company’s stock in a transaction on Wednesday, May 16th. The stock was bought at an average price of $6.46 per share, for a total transaction of $64,600.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $64,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of PTGX traded down $0.46 during mid-day trading on Thursday, hitting $5.99. The company’s stock had a trading volume of 259,926 shares, compared to its average volume of 209,881. Protagonist Therapeutics Inc has a 52-week low of $6.34 and a 52-week high of $6.50. The stock has a market capitalization of $136.76 million, a PE ratio of -2.87 and a beta of 3.54.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $10.78 million for the quarter, compared to analysts’ expectations of $10.70 million. equities analysts expect that Protagonist Therapeutics Inc will post -0.98 earnings per share for the current fiscal year.
PTGX has been the topic of a number of research analyst reports. BidaskClub downgraded shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 19th. Stifel Nicolaus initiated coverage on shares of Protagonist Therapeutics in a research note on Monday, January 29th. They issued a “buy” rating and a $32.00 target price on the stock. BMO Capital Markets restated an “outperform” rating and issued a $42.00 target price (down from $44.00) on shares of Protagonist Therapeutics in a research note on Thursday, March 8th. Finally, Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Tuesday, March 13th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $26.75.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.